Insights - Ohr Pharmaceutical (OHRP) on Tuesday released interim results from a phase 2 study of its Squalamine eye drops in Wet Age-related Macular Degeneration (AMD). Squalamine eye drops, … Continue Reading
Read nowInsights - The rejected bid is forcing Shire (SHPG) execs to issue longterm guidance, an uncommon practice in bio, and similar to what's going on at Allergan (AGN)
Read nowRecap - The “Hold Your Nose, Buy the Panic” crowd is being vindicated as biotech recovers from a 2-month correction, and makes its way towards old highs. … Continue Reading
Read nowInsights - Shire Plc (SHPG) confirmed before the open on Friday said that it has rejected a $46 billion bid from AbbVie (ABBV), which represented a 25% premium … Continue Reading
Read nowInsights - Insmed (INSM) announced on Wednesday that the FDA has granted Arikayce (liposomal amikacin), the company’s lead product candidate, Breakthrough Therapy Designation (BTD) for refractory nontuberculous mycobacterial (NTM) lung … Continue Reading
Read nowInsights - The U.S. FDA’s Advisory Gastroenterology and Urology Devices Panel (GUDP) voted on Tuesday 6 to 2 (one abstention) that the relative benefits of EnteroMedics’ (ETRM) VBLOC vagal blocking … Continue Reading
Read nowInsights - Flamel (FLML) quickly turned around a CRL received in late April for one of its pipeline drug candidates. That sets up a big event for August 6.
Read now
